Update February 2026. Before you read this, please note:
Why Practice Is Changing Faster Than the Guidelines
Modern peri‑operative management for neuroendocrine tumours is evolving rapidly, and several factors explain why clinical practice in some expert centres has moved ahead of formal guidelines:
1. New evidence challenges long‑held assumptions
Recent surgical series — most prominently from OHSU Portland USA — show that prophylactic octreotide does not reliably prevent carcinoid crisis and that crises behave more like distributive shock, responding better to vasopressors than to somatostatin analogues. This directly contradicts decades of dogma.
2. Guidelines update slowly by design
Bodies such as NANETS, ENETS, NCCN, UKINETS require:
– multiple independent data sources,
– consensus across disciplines,
– and formal review cycles.
Even strong new evidence can take years to filter into guideline revisions.
3. Crisis definitions were outdated
Older guidelines were built around vague or inconsistent definitions of “carcinoid crisis.” Modern analyses show that many events previously labelled as crisis were actually anaesthetic‑related hypotension, not serotonin‑mediated physiology. This mismatch makes older recommendations difficult to apply to contemporary practice.
4. Expert centres adapt quickly when evidence is clear
High‑volume NET surgical teams with experienced anaesthesia support can safely adopt new approaches before guidelines catch up. OHSU is the clearest example: they have formally abandoned prophylactic octreotide and rely on vasopressors for crisis‑like hypotension.
5. A new international consensus is in progress
Because existing guidelines no longer reflect modern evidence, an international Delphi process is underway to redefine:
– what constitutes a true carcinoid crisis,
– how to prevent it,
– and how to treat it effectively.
This work is expected to inform the next generation of guidelines.
Update November 2025.
This new document from the same surgeon and NET team below has further justified why they now adopt a totally different approach to nearly everyone else and they can back it up with evidence.
This followed the updated blog below “Do we need a new model for carcinoid crisis in NETs?“. It looks like they have deployed this ‘new model’ given their statement “Based on our research, at Oregon Health & Science University, we have entirely stopped using octreotide during operations, relying instead on vasopressors and treatment directed at managing distributive shock”.
Worth a read.
-
Intraoperative Carcinoid Crisis in NET Operations – Eluding Dogma with Current Understanding
Meuchel, Lucas W. et al.Surgical Oncology Insight, Volume 0, Issue 0, 100198
Update January 2024.
A study, initially presented at NANETS 2021 produced data to suggest the causes and treatment for carcinoid crisis have been wrong and that a new model is required. Since then, this theme has persisted and is making headway, at least in USA. Read the article here or by clicking on the picture.
Author’s note: This is probably a controversial conclusion in some circles and it’s worth pointing out that so-called ‘carcinoid crisis’ isn’t going away, just the need for time-consuming and expensive, and apparently ineffective according to the study, perioperative protection. And the study also noted that medication to treat complications was still required. I don’t believe we should immediately dismiss this conclusion as one of the authors is a ‘big hitter’ NET Specialist surgeon (Dr Rodney Pommier) whose job is to keep patients safe on the operating table.
The original article follows
The word ‘crisis’ has a wide range of meanings and it’s well used in the media to catch the reader’s attention. Lately, the terms ‘political crisis’, financial ‘crisis’ and ‘constitutional crisis’ appear almost daily in media headlines. In a previous life, the term ‘crisis management’ was used daily in the work I was undertaking as I went from problem to problem, dampening or putting out fires (….. that’s a metaphor!). Thinking back, my adrenaline (epinephrine), norepinephrine, and cortisol must have been very busy!
However, in the world of Neuroendocrine Tumours (NETs), ‘crisis’ has a very significant meaning, and its very mention will make ears prick up. The word ‘crisis’ is normally spoken or written using the term ‘Carcinoid Crisis’ given it is normally associated with those who have carcinoid syndrome. One might assume it only involves patients with tumours in locations previously described using the ancient term “carcinoid“. Perhaps this is another knock-on effect caused by the historical use of the word ‘Carcinoid‘ to incorrectly refer to all NETs. However, I’ve studied and researched and it would appear that some form of ‘crisis’ might apply to at least one other NET – Pheochromocytoma/Paraganglioma – a catecholamine-secreting group of tumours (see more below). Although this is a different variant of crisis situation, maybe there should be a more generic NETs wide term?
What is (so-called) ‘Carcinoid Crisis’?
In the simplest of terms, it is a dangerous change in blood pressure, heart rate, and breathing (technical term – cardiopulmonary hemodynamic instability). On an operating table under anaesthetics or an invasive procedure such as liver embolization, this can be an event that could worry both patient and doctor. Incidentally, this happens with many other types of conditions (…… hormones and peptides do exist in other illnesses). However, with a patient already oversecreting these hormones and peptides, it could be a risky affair.
What is the difference between carcinoid crisis and carcinoid syndrome?
A carcinoid crisis is said to be a situation where nearly all of the possible symptoms of carcinoid syndrome come at the same time and in some severity. Carcinoid crisis is a serious and life-threatening complication of carcinoid syndrome and is generally found in people who already have carcinoid syndrome. The crisis may occur suddenly, or it can be associated with stress, or a reaction to treatment, but it is mainly a result of the use of anaesthesia. There is probably a thin line between a severe bout of carcinoid syndrome and carcinoid crisis but generally, it can be characterized by an abrupt flushing of face and sometimes upper body, usually severe falls in blood pressure and even bronchospasm with wheezing can infrequently occur. The attack may look like a severe allergic reaction.
It is said by one very well-known NET expert to “not to be something which happens randomly to all patients, it is usually linked to a medical procedure of some sort when you are having anaesthesia”. Dr Eric Liu also said, “Luckily it is relatively uncommon”.
Why does it happen to some NET Patients?
NETs can release a variety of ‘vasoactive peptides’ (hormones) in excess (e.g. serotonin, tachykinins, vasoactive intestinal peptide (VIP), catecholamines, i.e. anything can directly affect blood vessel diameter and blood flow). Under normal circumstances in NET, these could present as routine syndromes which may need to be controlled.
Excess amounts of these vasoactive substances can cause both hypertension and hypotension (high and low blood pressure respectively). In extreme cases, this can lead to what is known as a crisis situation. Anaesthetists are trained to react to these situations during surgery.
How is the risk managed?
Most people are effectively managed on monthly injections of Octreotide/Lanreotide but some people still need ‘rescue shots’ (top-ups) when they are experiencing breakthrough symptoms. When I was symptomatic (syndromic), I would regularly flush in stressful situations but that was definitely syndrome rather than crisis. Check out my video explaining how I felt. It’s worth reading something called the 5 E’s of Carcinoid Syndrome, probably useful to other types of NETs as I’m sure there is some overlap (again the ‘carcinoid’ term is unintentionally used as a catch-all).
If you research this plus perhaps from your own experience, you will know there are different ideas and ‘protocols’. However, they all mostly involve some pre-procedure infusion of a somatostatin analogue (normally Octreotide) – although I’d love to hear from anyone who has had Lanreotide as an alternative. Some doctors or hospitals are known to have their own ‘protocols’ and I’ve uploaded the one from the ISI NET book page 215 (Wang, Boudreaux, O’Dorisio, Vinik, Woltering, et al). Click here. Please note this is an example rather than a recommendation as this is something the (then) NOLA team has developed for their own centre.
UKINETS guidance has a rather nice graphical guidance sheet click here
In all the big procedures I’ve had in my local NET Centre, I have always been admitted the day before to receive what they describe as an ‘Octreotide Soak’. The link below is an example of the UK standard for pre and peri-operative protection (please note your NET team may be working to a slightly different protocol based on their own version of best practice, just to emphasise that this is an example and not advice).
I did not have protection for some procedures prior to diagnosis (even when in hindsight I had carcinoid syndrome), and after my diagnosis. Additionally, I don’t need anything special for dental procedures involving epinephrine. There have been no incidents.
What about minor procedures?
Patients are always asking about the risk and requirements for smaller procedures such as an Endoscopy. There does not seem to be common guidance on this but Dr Woltering who is always forthcoming with advice suggests 200 micrograms of Octreotide before the procedure commences. Looking at the UKINETS guidance click here, there appears to be a less risk-averse approach by considering whether patients are symptomatic or not (syndromic or not).
The Dentist
A frequently answered question and nothing is contained in any national guidelines (to me that says there is not a huge connection). Epinephrine is one of the so called “5 Es of carcinoid syndrome” (so technically should only affect those with serotonin secreting NETs). The only advice on this comes from known specialist Dr Woltering and everything is contained in my blog about the 5 Es of Carcinoid Syndrome. Additionally, in that blog there is also info for users of ‘Epi Pens’. You may need to de-risk those situations.
What about other types of NETs
This is a grey area because of the word “carcinoid” which technically only covers serotonin secreting tumours and carcinoid syndrome. However, the new study I linked above would appear to take another view.
I know that NET patients other than those with ‘Carcinoid Syndrome causing tumours’ are also treated with somatostatin analogues, as they too can be subject to the effects of excess secretion of certain vasoactive peptides. Once again, the word ‘Carcinoid’ causes confusion. There are many types of NET that were never called ‘Carcinoid’ and this had led to great confusion. We need to call it something like Hormonal Crisis to avoid this confusion. I did note that Novartis (AAA) actually call it that in the Lutathera instructions – well done them!
Why is the issue relative to Pheochromocytoma/Paraganglioma?
Pheochromocytomas and paragangliomas are catecholamine-producing neoplasms that can cause life-threatening hemodynamic instability, particularly intraoperatively, when the tumour is manipulated. In some ways, their version of ‘crisis’ is more complex and dangerous than the issues with ‘carcinoid crisis’ above. There needs to be significant pre-operative preparation in addition to peri-operative measures, in fact with this type of tumour, post-surgical treatment and monitoring is also required.
I recently read an article about a person with Pheochromocytoma. The person had what was described as an ‘Intraoperative Hypertensive Crisis‘ that appeared to be caused by her tumour type rather than the sort of incident that might occur in standard surgery. Hypertension (high blood pressure) can be a symptom of Pheochromocytoma so you can see the problem with surgery and other procedures. An interesting issue with this type of NET is that after surgery, the patient is at risk for hypotension (low blood pressure) from venous dilation caused by the sudden withdrawal of catecholamines. Read more here.
Summary
I highly suspect there are many examples from the NET world beyond what was once called the ‘carcinoid’ subtype of NETs and I’ve already given you at least one above. I’ll update this post as I discover other examples. In the meantime, make sure you ask your medical team about ‘crisis protection’ if you are to undergo any surgical or invasive medical procedure. Minor procedures should also be assessed.
Do we need to rename the term Carcinoid Crisis to Neuroendocrine Crisis or Hormonal Crisis? Absolutely right we do! We also need the big scientific organisations (ENETS/NANETS etc) to be more vocal on this subject given the confusion and lack of boundary to this issue above.
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional. Some content may be generated by AI which can sometimes be misinterpreted. Please check any references attached.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
.
Click here and answer all questions to join my private Facebook group
Facebook – Neuroendocrine Cancer
Ronny
Check out my WEGO Health Awards
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
- Spotlight on Thymic Neuroendocrine Neoplasms (Thymic NENs)
Disclaimer:The information in this Spotlight is for general education and awareness. It does not replace personalised medical advice, diagnosis, or treatment. Thymic Neuroendocrine Neoplasms (NENs) are complex and highly variable, and individual cases may differ significantly from the patterns described here. Always discuss your own situation, test results, and treatment options with your specialist team,… Read more: Spotlight on Thymic Neuroendocrine Neoplasms (Thymic NENs) - An unmissable update from Ronny Allan covering April 2026
A monthly update not to miss……..Summary of April 2026 on RonnyAllan.NET I think the main story of April is similar to March which was a strong blog performance. Some of March was so popular that it has rolled into April and I have tried to beat those figures but failed due to external pressures. Nonetheless, the… Read more: An unmissable update from Ronny Allan covering April 2026 - Spotlight on Small intestine Neuroendocrine Neoplasms (siNENs)
DisclaimerThis Spotlight is for general education and reassurance only. It cannot replace personalised advice from your own medical team, who understand your individual history, imaging, pathology, and treatment needs. Neuroendocrine tumours vary widely in behaviour, presentation, and management, and guidance may evolve as new evidence emerges. If you have questions about your diagnosis, symptoms, or… Read more: Spotlight on Small intestine Neuroendocrine Neoplasms (siNENs) - A Spotlight on Pancreatic Neuroendocrine Neoplasms
DisclaimerThe information in this Spotlight is for general education only. It cannot replace advice from your own medical team, who know your individual situation, test results, and treatment options. Neuroendocrine Neoplasms and related conditions are complex and research is evolving; guidance, classifications, and statistics may change over time. Always discuss any questions or concerns with… Read more: A Spotlight on Pancreatic Neuroendocrine Neoplasms - Neuroendocrine Cancer in UK – a growing crisis?
I was delighted to read about the efforts of Dr Arthur Scott, a Member of the UK Parliament (MP). He is a great advocate for cancer patients and recently introduced a rare cancer bill in the UK Parliament which will hopefully make a difference. The content was very interesting and I was drawn to several… Read more: Neuroendocrine Cancer in UK – a growing crisis? - Bone Metastases in Well‑Differentiated NETs – Part 2 – Treatment
DisclaimerThis information is for education and reassurance only.It is not a substitute for personalised medical advice, diagnosis, or treatment. Bone metastases in neuroendocrine tumours (NETs) vary widely in behaviour, appearance, and clinical significance. Decisions about systemic therapy, radiotherapy, ablation, bone‑targeted agents, surgery, or monitoring must be made by your own specialist NET team, who understand… Read more: Bone Metastases in Well‑Differentiated NETs – Part 2 – Treatment - Neuroendocrine Tumours – Vitamin B3 (Niacin)
Before you read thisThis information is designed to help you understand how vitamins work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely. If you have concerns… Read more: Neuroendocrine Tumours – Vitamin B3 (Niacin) - March 2026 Newsletter from Ronny Allan
Here is my monthly summary of March 2026 on RonnyAllan.NET This has been a very good month but to be honest, I had more time at home and on my computer, due to illness. OK I was not that ill that I could not tap away at a keyboard! However, it was pretty erratic access. I… Read more: March 2026 Newsletter from Ronny Allan - Understanding Differentiation, Ki‑67, Mitotic Count, Hotspots, Pathology Workflow, and Primary–Metastasis Heterogeneity in Neuroendocrine Neoplasms (NENs)
Before you read this… This article discusses pathology concepts such as Ki-67, grading, heterogeneity, and biopsy findings in neuroendocrine tumours (NETs). It is provided for educational purposes only and does not interpret any individual pathology report or scan result. Ki-67 values, tumour grade, and sampling limitations can vary between different biopsies and over time. Their… Read more: Understanding Differentiation, Ki‑67, Mitotic Count, Hotspots, Pathology Workflow, and Primary–Metastasis Heterogeneity in Neuroendocrine Neoplasms (NENs) - Why liver transplant is back in the NET conversation
Before you read this… This article is provided to support understanding of a complex and evolving topic. It explains how liver transplant is being explored in a very small number of NET patients, but it is not suggesting that this treatment is suitable for you or anyone else. Every NET case is unique. Only your… Read more: Why liver transplant is back in the NET conversation - This too shall pass
If you’ve heard that phrase before, you’re not alone. The phrase is rooted in older Persian and Buddhist teachings, and widely accepted as a testament to the impermanence of all things. Many famous people have used this phrase including Abraham Lincoln, Tom Hanks, Robert De Niro and King Solomon. I’ve also seen various cancer bloggers… Read more: This too shall pass - HRT and Neuroendocrine Tumours (NETs): What Patients Need to Know
Before you read this… This article discusses hormone replacement therapy (HRT) in the context of general health, menopause, and neuroendocrine tumours (NETs). It is provided for educational purposes only and does not recommend starting, stopping, or changing any form of HRT. The suitability of HRT depends on many individual factors, including tumour type, grade, hormone… Read more: HRT and Neuroendocrine Tumours (NETs): What Patients Need to Know - Blood Clot risks in Neuroendocrine Neoplasms (NENs)
I have a personal interest in this subject because I had pulmonary emboli (PE) diagnosed in January 2011 around 6 weeks after I had major surgery. I got a phone call from the hospital to go down that day and meet with a nurse who would teach me to self inject ‘Clexane'(Enoxaparin) and then take… Read more: Blood Clot risks in Neuroendocrine Neoplasms (NENs) - Neuroendocrine Tumours (NETs) – Vitamin D (Cholecalciferol / Ergocalciferol)
Before you read thisThis information is designed to help you understand how vitamins work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely.If you have concerns about… Read more: Neuroendocrine Tumours (NETs) – Vitamin D (Cholecalciferol / Ergocalciferol) - Cancer: Words are important but so is context
Words are very important to cancer patients, some people hang their hats on them and put their feet up, and some people google them until they are tied in a knot, still fraught with worry. Why can’t doctors just tell me in layman’s language? Easy answer ……. because it is not an exact science. Doctors… Read more: Cancer: Words are important but so is context - Newsletter covering January and February 2026
Overview Many thanks for the support in January and February 2026. This is a double month newsletter due to my 27 day holiday! 2026 Blog Activity for January and February Actually, despite my holiday figures are pretty much normal. I had a great month in December 2025, perhaps I was overperforming as I was anticipating… Read more: Newsletter covering January and February 2026 - Neuroendocrine Tumours (NET) – Vitamin B12 (Cobalamin)
Before you read thisThis information is designed to help you understand how vitamins work in the body and how certain NET-related factors might affect them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs can vary widely.If you have concerns about… Read more: Neuroendocrine Tumours (NET) – Vitamin B12 (Cobalamin) - Sometimes you gotta climb that bridge!
When I was a young lad, I didn’t seem to have a fear of heights, not that I got many chances to test it but a couple of things springs to mind. As a ‘feral youth’ I once climbed to the top of a factory building without fear. I won’t divulge any further detail, just… Read more: Sometimes you gotta climb that bridge! - 50 years of marriage – in sickness and in health
When I was diagnosed with metastatic Neuroendocrine Cancer in 2010, there’s a lot of milestones I doubted I would reach. One is today and I can now tick off another and be thankful for reaching it. I have been married to a kind and beautiful lady for 50 years on – 29th March 2025. I’ve… Read more: 50 years of marriage – in sickness and in health - Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (STELLAR-311)
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors. The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors. Zanzalintinib (XL092) is an investigational,… Read more: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors (STELLAR-311) - Next Generation Total-Body PET/CT: Challenges and Opportunities
Long-axial field-of-view (LAFOV) systems have changed the field of molecular imaging. Since their introduction, many PET centres have installed these next-generation digital systems to provide more detailed imaging and acquire PET images in a single bed position. Indeed, vertex to thigh imaging for oncological indications can be obtained in most of the population with the… Read more: Next Generation Total-Body PET/CT: Challenges and Opportunities
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts sent to your email.





Having neuroendocrine tumour is so lonely.
If you’re on Facebook, I have over 6000 members. It’ll might make you less lonely. https://www.facebook.com/groups/RonnyAllan.NeuroendocrineCancer/
Ronny Allan. My husband had a complete pancreatectomy, splenectomy, along with all gall he bladder removed, part of liver removed, part of stomach removed, part of colon removed. We believe all neuroendocrine tumors are gone. However, 1 week after surgery something happened at the hospital and they used epi off the crash cart, told me they needed a heart cath and a CT of the lung. Nothing showed up. Now ( a year later, after reading many of your posts) I’m wondering if this could have been a carcinoid crisis. He has several small procedures to place tubes and drains. Never had any problem since. He was moved to a different hospital after that had occured. What do you think? Can you have “carcinoid crisis” if the tumors are gone? Or maybe it was something else. Or maybe, he still has net somewhere?? ( I hope not🙏) myuhaszpratt@yahoo.com.
These things can happen to anyone in surgery, not just NETs but one week after surgery is odd. I suppose if he was in hospital, there’s a potential connection but my gut feeling is that this wasn’t a “carcinoid crisis”. Was his 5HIAA level elevated?
I recently had a liver embolization this wee and had a carcinoid crisis nearing the end of the procedure.. I did talk to the group before hand but they did not administer it before procedure. Did have it in the room when it happened. Very scared and this will not happen again. Love your blog.
Oh dear Margie, hope you’re doing OK.